Fig 1: pMVP enables rapid, high-fidelity assembly of custom multicomponent transgene vectors. (A) The pMVP platform provides an array of Entry plasmids (pENTR) for promoters (6 options), 5′ modifiers (27 options), and 3′ modifiers (65 options) that can be partnered with a gene of interest and rapidly recombined into (B) an assortment of cross-compatible destination vectors (35 options) via an overnight recombination reaction to form (C) a customized experimental vector. In total, >108,000 unique vector permutations are possible for a gene of interest that is incorporated into pMVP. The resulting adenovirus (Ad), lentivirus (Lenti), Expression plasmid, Sleeping Beauty Transposon (SB), and PiggyBac transposon (PB) experimental vectors can be utilized in a broad variety of experimental contexts. (D) pMVP-derived vectors containing an EF1a promoter driving eGFP-P2A-PDX1-3xHA and either a polyA or WPRE were generated and added to primary (rat islet) or immortalized (HEK293) cells for either transient (adenovirus; expression) or stable (lentivirus, Sleeping Beauty, PiggyBac) transgene expression experiments. Cellular lysates were harvested for immunoblot analysis at the indicated times after viral transduction or plasmid transfection.
Fig 2: Utilization of pMVP for the creation of unique PDX1 vectors. pENTR plasmids containing cDNA for human PDX1 with or without a stop codon (i.e. open) were recombined with pMVP components to generate an assortment of PDX1-expressing (A) adenovirus and (C) expression plasmid vectors. (B) Immunoblot blot analysis of INS1 832/13 cell lysates harvested 48h after treatment with crude adenovirus lysates. For the epitope tagged conditions, note the appearance of the endogenous (lower) and overexpressed (upper) PDX1 bands (top blot). For eGFP blot, the use of P2A adds 23 amino acids to the N-terminal protein (i.e. eGFP). Immunoblot analysis of HEK293 cell lysates 24 h after transfection of expression vectors encoding PDX1 with C-terminal (D) epitope tags, (E) eGFP reporter or fusion, (G) and mCherry reporter or fusion. (F, H) Fluorescence microscopy of the eGFP and mCherry containing conditions analyzed in panels E and G. Visible bands resulting from ‘Uncleaved’ P2A products (red circle •) and degradation products (*) are labeled.
Fig 3: Impact of Pdx1 and MafA silencing on the expression of MAPK8IP1 in INS-1 cells. Cells were transfected with siRNA against Pdx1 (siPdx1) or MafA (siMafA), or the siRNA negative control (siNC). (A) Silencing efficiency of Pdx1 in INS1 cells 48 h post-transfection as measured by qRT-PCR. (B) Silencing efficiency of MafA in INS1 cells 48 h post-transfection as measured by qRT-PCR qPCR. (C–E) Western blot analysis of PDX1 (C), MAFA (D) and MAPK8IP1 (E) in Pdx1 or MafA-silenced cells and control cells relative to the endogenous control protein β-actin (lower panels). Corresponding fold changes in the intensities of the Western blot bands are shown above each blot. Data were obtained from three independent experiments (see Supplementary Figures S5–S7). * p < 0.05, ** p < 0.01, *** p < 0.001, ns; not significant. Bars above histograms represent SD of the mean values. Statistical analyses were performed using Student t-tests.
Fig 4: Expression analysis of AHR in human pancreatic islets. (A) RNA-seq expression of AHR, KCNJ11, PDX1, INSR, MAFA, GCK, and GLUT1 in human islets obtained from non-diabetic donors (n = 49). (B). AHR expression levels in human islets obtained from diabetic/hyperglycemic donors (n = 25) compared to nondiabetic/normoglycemic islet (n = 49) donors. (C) AHR expression levels in human islets obtained from lean donors (n = 18; BMI below 24) compared to obese donors (n = 19; BMI above 29). (D) AHR expression levels in human islets obtained from male donors (n = 53) compared to female donors (n = 33). Correlation of AHR expression with HbA1c% (n = 66) (E), BMI (n = 87) (F), or age (n = 87) (G). *; p > 0.05, ns; not significant. Bars represent mean ± SEM. Nonparametric Mann–Whitney t-tests were used in (B–D). Nonparametric Spearman’s correlation test was used in (E–G).
Fig 5: VMEL contribution to multiple foregut organ buds occurs in a temporally restricted manner. A–B, H–I, O–P. Bright field/fluorescent merged views of embryos labeled with DiI (red) in the VMEL at the onset (A, H, O) and after ∼30 hours of culture (B, I, P). All embryos were sectioned as indicated (dashed lines in B, I and P) and immunofluorescence performed with PDX1 (green) to identify the ventral pancreas bud. Thyroid buds (C, J, Q) and different portions of the liver bud (rostral liver in D, K, R and liver bud in E, L, S) were identified based on morphology. All sections are presented at low magnification (C–F, J–M, Q–T) and a portion of this field (indicated by the boxed area) presented at high magnification (C’–F’, J’–M’, Q’–T’) where the indicated tissue bud has been outlined by a dotted line and arrowheads used to point to DiI labeled cells within the indicated tissue bud. G, N, U. Cartoons summarizing the VMEL contribution (red line) to the thyroid bud (thb), liver bud (lb) and ventral pancreas bud (vpb) for the embryo to the left of the cartoon. A–G. This 5 SS VMEL labeled embryo (red, A) was cultured through the 19 SS (B). Section analysis of this embryo revealed DiI contribution to the thyroid (C, C’), a swath of cells in the rostral liver (D, D’) and a limited number of cells in the midline of the liver (E, E’) and ventral pancreas buds (F, F’) as summarized in G. H–N. The VMEL labeled 5 SS embryo (H) was cultured through the 23 SS (I). Section analysis reveals no VMEL contribution to the thyroid bud (J, J’) but the presence of VMEL descendants in a swath of rostral liver bud (K, K’), in the midline of the liver bud (L, L’) and in the midline of the ventral pancreas bud (M, M’) as summarized (N). O–U. This 8 SS embryo (O) was DiI labeled in the VMEL and cultured through the 28 SS (P). Although labeled VMEL descendants were not found in the thyroid (Q, Q’) or rostral liver buds (R, R’) they were found in the midline of the liver (S, S’) and ventral pancreas buds (T, T’) as summarized (U). v = ventral and d = dorsal gut tube, h = heart.
Supplier Page from Abcam for Anti-PDX1 antibody